medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 2

<< Back Next >>

Med Int Mex 2023; 39 (2)

Plasmacytoid dendritic cell blast neoplasia

Wuotto-Alvarado S, Martínez-Murillo AC, Sánchez-Barrera MD, Hernández-Salcedo DR, Valencia-López R, Castro-Guzmán CL, Toussaint-Caire S

Language: Spanish
References: 13
Page: 402-407
PDF size: 276.13 Kb.


ABSTRACT

Background: Plasmacytoid dendritic cell blast neoplasia is a malignant neoplasm of hematopoietic origin, representing 0.7% of primary cutaneous hematological neoplasms. Skin lesions are the first manifestation. The diagnosis requires immunophenotypic analysis, clinical and histopathological correlation. So far there is no standardized treatment.
Clinical case: A 92-year-old male patient with dermatosis on the face, mucosa, trunk and upper extremities characterized by multiple macules and erythematous-violaceous plaques, associated with wasting syndrome.
Conclusions: The aforementioned case reports a diagnosis of plasmacytoid dendritic cell blast neoplasia, which is a rare entity, difficult to diagnose, with a reduced life expectancy and a poor short-term prognosis. A timely diagnosis should be made, since the treatment to be offered and survival in the short term will depend on this.


REFERENCES

  1. Khoury JD. Blastic plasmacytoid dendritic cell neoplasm.Curr Hematol Malig Rep. 2018;13(6):477–83.

  2. Sapienza MR, Pileri A, Derenzini E, Melle F, Motta G, FioriS, et al. Blastic plasmacytoid dendritic cell neoplasm: Stateof the art and prospects. Cancers (Basel) 2019; 11 (5): 1-16.doi: 10.3390/cancers11050595.

  3. Silveira SO, Fernandes CMA, Pinto EB, Einecke YS, PalhetaCDSA, Brito CVB, et al. Blastic plasmacytoid dendritic cellneoplasm: An early presentation. Dermatol Online J 2019;25 (2): 0-3.

  4. Venugopal S, Zhou S, El Jamal SM, Lane AA, MascarenhasJ. Blastic plasmacytoid dendritic cell neoplasm–currentinsights. Clin Lymphoma Myeloma Leuk 2019; 19 (9): 545-54. doi: 10.1016/j.clml.2019.06.002.

  5. Kameoka J, Ichinohasama R, Tanaka M, et al. A cutaneousagranular CD2- CD4+ CD56+ “lymphoma”: report of twocases and review of the literature. Am J Clin Pathol 1998;110: 478-488. doi: 10.1093/ajcp/110.4.478.

  6. Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiologyand survival of blastic plasmacytoid dendritic cellneoplasm. Leuk Res 2018; 73: 21-3. doi: 10.1016/j.leukres.2018.08.014.

  7. Piña-Oviedo S, Ortiz-Hidalgo C. Neoplasia hematodérmicaCD4+/CD56+. Diagnóstico histopatológico, fisiopatología yavances recientes de un tumor originado en células dendríticasplasmocitoides. Rev Española Patol 2007; 40 (1):11-22. https://doi.org/10.1016/S1699-8855(07)70051-X.

  8. Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, EtebariM, et al. Blastic plasmacytoid dendritic cell neoplasm:Genomics mark epigenetic dysregulation as a primarytherapeutic target. Haematologica 2019; 104 (4): 729-37.doi: 10.3324/haematol.2018.202093.

  9. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blasticplasmacytoid dendritic cell neoplasm: Diagnostic criteriaand therapeutical approaches. Br J Haematol 2016; 174(2): 188-202. doi: 10.1111/bjh.14146.

  10. Lyapichev KA, Sukswai N, Konoplev S, Khoury JD. Blasticplasmacytoid dendritic cell neoplasm with unusual lymphoidfeatures and macrovacuoles. Ann Hematol 2019; 98(9): 2221-2. doi: 10.1007/s00277-019-03675-1.

  11. Falcone U, Sibai H, Deotare U. A critical review of treatmentmodalities for blastic plasmacytoid dendritic cell neoplasm.Crit Rev Oncol Hematol 2016; 107 (2016): 156-62. doi:10.1016/j.critrevonc.2016.09.003.

  12. Kerr D, Sokol L. The advances in therapy of blastic plasmacytoiddendritic cell neoplasm. Expert Opin InvestigDrugs 2018; 27 (9): 733-9. https://doi.org/10.1080/13543784.2018.1512970.

  13. Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, BlumW, et al. Tagraxofusp in blastic plasmacytoid dendritic-cellneoplasm. N Engl J Med 2019; 380 (17): 1628-37. DOI:10.1056/NEJMoa1815105.




2020     |     www.medigraphic.com